Shopping Cart
Remove All
Your shopping cart is currently empty
FXR agonist 15
Catalog No. T214219 Copy Product Info
🥰Excellent
FXR agonist15 is a selective, potent, orally active farnesoid X receptor (FXR) agonist with an EC50 of 0.76 μM. It does not significantly activate other nuclear receptors such as LXRα/β, PXR, PPARα/β/γ, and THR-β, with EC50 values exceeding 10 μM for each. FXR agonist15 is effective in alleviating symptoms like steatosis, lobular inflammation, hepatocellular ballooning, and liver fibrosis. It is applicable in research studies related to non-alcoholic steatohepatitis (NASH).
FXR agonist 15
Copy Product Info🥰Excellent
Catalog No. T214219
FXR agonist15 is a selective, potent, orally active farnesoid X receptor (FXR) agonist with an EC50 of 0.76 μM. It does not significantly activate other nuclear receptors such as LXRα/β, PXR, PPARα/β/γ, and THR-β, with EC50 values exceeding 10 μM for each. FXR agonist15 is effective in alleviating symptoms like steatosis, lobular inflammation, hepatocellular ballooning, and liver fibrosis. It is applicable in research studies related to non-alcoholic steatohepatitis (NASH).
FXR agonist 15
Cas No. 2991276-14-1
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | FXR agonist15 is a selective, potent, orally active farnesoid X receptor (FXR) agonist with an EC50 of 0.76 μM. It does not significantly activate other nuclear receptors such as LXRα/β, PXR, PPARα/β/γ, and THR-β, with EC50 values exceeding 10 μM for each. FXR agonist15 is effective in alleviating symptoms like steatosis, lobular inflammation, hepatocellular ballooning, and liver fibrosis. It is applicable in research studies related to non-alcoholic steatohepatitis (NASH). |
| In vivo | FXR agonist 15 (Compound 19) administered at 20 mg/kg orally once daily for 4 weeks can alleviate NASH induced by WD and CCl4, reducing liver steatosis, inflammation, and fibrosis. Furthermore, FXR agonist 15 at 500 mg/kg orally once daily for 10 days in ICR mice showed no mortality or abnormal behavior, with serum liver and kidney function markers (AST, ALT, ALP, creatinine, urea) and lipid markers (TG, TC) remaining normal. No acute toxic damage to major organs was observed, indicating good safety. |
| Molecular Weight | 526.4 |
| Formula | C24H22Cl2FNO5S |
| Cas No. | 2991276-14-1 |
| Smiles | O=C(O)COC=1C=CC(=CC1F)C2=CC=C(C=C2)N(CC(C)C)S(=O)(=O)C=3C(Cl)=CC=CC3Cl |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Citations
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy FXR agonist 15 | purchase FXR agonist 15 | FXR agonist 15 cost | order FXR agonist 15 | FXR agonist 15 in vivo | FXR agonist 15 formula | FXR agonist 15 molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.